FY results highlight Summit’s advancing pipeline as a pure-play developer of new-mechanism antibiotics, Ridinilazole (targeting C. difficile infection, an area of unmet need due to high recurrence rates) recently entered Phase III trials, and we continue to expect SMT-571 (targeting N. gonorrhoeae infection, already on its last treatment option as a result of high and rising antibiotics resistance) to enter Phase I trials by year-end. In addition, encouraging development progress is being made o ....
27 Mar 2019
FY results reflect expanding pipeline of new-mechanism antibiotics
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY results reflect expanding pipeline of new-mechanism antibiotics
Summit Therapeutics Inc (SMMT:NAS) | 0 0 0.0%
- Published:
27 Mar 2019 -
Author:
Jens Lindqvist -
Pages:
3
FY results highlight Summit’s advancing pipeline as a pure-play developer of new-mechanism antibiotics, Ridinilazole (targeting C. difficile infection, an area of unmet need due to high recurrence rates) recently entered Phase III trials, and we continue to expect SMT-571 (targeting N. gonorrhoeae infection, already on its last treatment option as a result of high and rising antibiotics resistance) to enter Phase I trials by year-end. In addition, encouraging development progress is being made o ....